Yes. Semaglutide is a compounded prescription preparation dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, medical intake, and provider evaluation are required to screen for contraindications and establish an individualized titration protocol.

Common side effects are predominantly gastrointestinal and most frequent during dose escalation — including nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite, and dyspepsia. Most patients find these effects diminish as the body adjusts to each dose level. Injection site reactions may occur. Hypoglycemia risk is low when Semaglutide is used alone but increases significantly when combined with insulin or sulfonylureas. Post-marketing reports have described mood changes in some patients on GLP-1 agents; those with a psychiatric history should be monitored. Report all side effects to your provider promptly.

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients with known hypersensitivity to semaglutide, cyanocobalamin, or any component of the formulation should not use this preparation. Those with Leber's hereditary optic neuropathy should not receive cyanocobalamin-containing preparations without specialist evaluation. This medication is contraindicated during pregnancy. Patients with a history of pancreatitis, severe gastroparesis, or significant renal or hepatic dysfunction require individualized provider assessment.

Semaglutide's gastric-emptying delay can reduce absorption and alter timing of orally administered medications including oral contraceptives, thyroid hormone, and warfarin. Patients on insulin or sulfonylureas face elevated hypoglycemia risk when Semaglutide is added — dose reductions of those agents are often needed. Metformin reduces B12 absorption over time, making the cyanocobalamin component particularly relevant for patients on this medication. Discuss all current medications with your provider before beginning treatment.

Patients with a personal or family history of medullary thyroid carcinoma or MEN2 must not use Semaglutide. Those with type 1 diabetes, pancreatitis history, or significant renal or hepatic conditions require careful individualized review. Patients with cardiovascular disease may be treated under close provider supervision. Your provider requires a complete medical history before prescribing and will determine suitability based on your individual profile.